Dr. Imperiale is a Professor of Medicine in IU School of Medicine’s Division of Gastroenterology/Hepatology. As a physician scientist in the IU Center for Health Services and Outcomes Research, the VA HSR&D Center of Excellence on Implementing Evidence-Based Practice, and in Regenstrief Institute's Center for Health Services Research, he pursues primary research interests including tailoring screening for colorectal cancer based on individual patient risk, and using quantitative research methods in studying prevention of the complications of cirrhosis. Secondary research interests include prognosis and management of acute upper gastrointestinal hemorrhage, and assessment of new technologies to the application of digestive diseases.

     Dr. Imperiale received the Indiana University Trustee Teaching Award in 2004. He is a named Fellow in the American Gastroenterological Association and Member of the Association of American Physicians.

Dr. Imperiale is board certified in Internal Medicine and a staff physician at the Richard L. Roudebush VA Medical Center in Indianapolis, Indiana.

Indiana University Health Profile

CLINICAL INTERESTS

HOSPITALS & AFFILIATIONS

EDUCATION

Active Projects

I. American Digestive Health Foundation               07/01/2000 - 06/30/2012

"The Hugh R. Butt Award in Hepatology and Nutrition

II. Exact Sciences Corporation                              11/18/2011 - 12/31/2012

"Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advance Adenomatous Polyps and Cancer: DeeP-C Study" Services Agreement

III. Walther Cancer Foundation                             01/01/2011 - 12/31/2011

"Quantifying Risk of Advanced Colorectal Neoplasia to Target Screening Colonoscopy"

1. Imperiale TF. Screening elders for colorectal cancer: How much is enough? Arch Intern Med Aug 8/22, 2011; 171: 1332 - 1334.
2. Imperiale TF. The average-risk age threshold for colorectal cancer screening: should it be lowered? Dig Dis Sci 2011; 56(5):1249-51.
3. Juluri R, Eckert G, Imperiale TF. Polyethylene glycol vs sodium phosphate for bowel preparation. A treatment arm meta-analysis of randomized controlled trials.  BMC Gastroenterol 2011; 11:38.
4. Kahi CJ, Anderson JC, Waxman I, Kessler WR, Imperiale TF, Li X, Rex DK.  High-definition chromocolonoscopy vs. high-definition white light colonoscopy for average-risk colorectal cancer screening.  Am J Gastroenterol 2010 Feb 23 [Epub ahead of print]. [PMID 20179689]
5. Imperiale TF, Ransohoff DF.  Understanding differences in the guidelines for colorectal cancer screening. Gastroenterology 2010; 138(5):1642-1647.
6. Imperiale TF. Continue or discontinue warfarin for fecal occult blood testing in 2010? Does the published evidence provide an answer? Am J Gastroenterol 2010; 105(9):2036-9.
7. Morelli MS, Miller JS, Imperiale TF. Colonoscopy performance in a large private practice: a comparison to quality benchmarks. J Clin Gastroenterol 2010; 44:152-3.
8. Kahi CJ, Imperiale TF, Juliar BE, Rex DK. Effect of screening colonoscopy on colorectal cancer incidence and mortality. Clin Gastroenterol & Hepatology 2009; 7(7):770-775.
9. Haggstrom DA, Imperiale TF. Surveillance approaches among colorectal cancer survivors after curative-intent. Minerva Gastroenterologica e Dietologica 2009; 55(4):483-500.
10. Imperiale TF, Glowinski EA, Juliar BE, Azzouz F, Ransohoff DF. Variation in polyp detection rates at screening colonoscopy. Gastrointest Endosc 2009;69:1288-95.
11. Imperiale TF, Glowinski EA, Lin-Cooper CY, Larkin GN, Rogge JD, Ransohoff DF. Five-year risk of colorectal neoplasia after negative screening colonoscopy. N Engl J Med 2008; 359:1218-1224. [PMCID 18799558]
12. Imperiale TF, Kahi, CJ, Stuart JS, Qi R, Born LJ, Glowinski EA, Rex DK. Risk factors for advanced sporadic colorectal neoplasia in persons younger than age 50. Cancer Detect Prev 2008; 32(1):33-38. [PMCID 18400417]